Combining Value, Growth and Momentum
10x Stocks - Searching for multibaggers
  • Blog
  • Performance
  • Investment strategy
  • About

10 Biotech stocks bought by insiders

6/24/2014

0 Comments

 
Insider buying is many times a good indicator if the future direction of a stock. After all, insiders know the most about their company and as such can usually estimate it's value. Let's take a look at biotech stocks bought by insider in the past year (min. market cap 300 million):

10. Incyte Corporation

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs primarily for oncology and inflammation.

Market Cap: $9.4 billion
Insider buying: 51.35%
Shares float: 150 million
Insider ownership: 0.8%
P/B: -
Picture
9. Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. 

Market Cap: $9.4 billion
Insider buying: 57.7%
Shares float: 145 million
Insider ownership: 0.5%
P/B: 6.5
Picture
8. PDL Biopharma

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases.

Market Cap: $1.5billion
Insider buying: 61.2%
Shares float: 160 million
Insider ownership: 0.4%
P/B: 7.3
Picture
7. Kindred Bioscences

They focus on the development of therapies for pets. The company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses.

Market Cap: $372
Insider buying: 61.5%
Shares float: 16
Insider ownership: 0.2%
P/B: 5.2%
Picture
6. Insys Therapeutics

The company isa a commercial-stage specialty pharmaceutical company, develops and commercializes supportive care products.

Market Cap: $998 million
Insider buying: 66%
Shares float: 34 million
Insider ownership: 0.9%
P/B: 10
Picture
5. Synta Pharmaceuticals

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases.

Market Cap: $402 million
Insider buying: 68.4%
Shares float: 57 million
Insider ownership: 3.3%
P/B: 9.6
Picture
4. Cell Therapeutics

CTI BioPharma Corp., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer.

Market Cap: $452 million
Insider buying: 69.7%
Shares float: 124 million
Insider ownership: 4.6%
P/B: 16.7
Picture
3. Repros Therapeutics

Repros Therapeutics Inc., a development stage biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders in the United States.

Market Cap: $393 million
Insider buying: 76.3%
Shares float: 22.5 million
Insider ownership: 0.1%
P/B: 5.7%
Picture
2. Theravance

Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement with Glaxo Group Limited (GSK). 

Market Cap: $3.3 billion
Insider buying: 81%
Shares float: 78 million
Insider ownership: 3.4%
P/B: 12.3
Picture
1. XOMA Corporation

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Its proprietary products comprise gevokizumab, a humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III studies for non-infectious uveitis. The company has various other products in it's pipeline.


Market Cap: $509.9 million
Insider buying: 136.7%
Shares float: 99.5 million
Insider ownership: 0.8%
P/B: 238.5
DOWNLOAD THE EXCEL SPREADSHEET FOR MORE INFORMATION
Picture
0 Comments



Leave a Reply.

    To make money in stocks you must have the "the vision to see them, the courage to buy them and the patience to hold them". And patience is the rarest of the three.  Thomas Phelps

    Follow @BestStocksNow

    Categories

    All
    Best Stocks Of 2013
    Best Stocks Of 2014
    HK Stocks
    Indian Stocks
    Long
    Uk Stocks
    US Stocks

    Archives

    April 2021
    January 2021
    September 2020
    August 2020
    May 2020
    August 2019
    July 2019
    June 2019
    February 2019
    May 2018
    August 2017
    July 2016
    February 2016
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    September 2014
    August 2014
    July 2014
    June 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013

    RSS Feed

Powered by Create your own unique website with customizable templates.